Catalent buys Paragon in hot gene medicine market

The US’s Catalent will buy Paragon Bioservices in a debt and equity financed $1.2bn deal, as consolidation in the gene therapy market builds pace.

  • By Mike Turner
  • 15 Apr 2019

Catalent makes advanced delivery technologies and development solutions for drugs, biologic products and consumer health products. Paragon is involved in manufacturing products for gene therapy.

Catalent will finance the transaction using a $650m term loan and by issuing $650m of convertible preferred stock to funds linked to private equity firm Leonard Green & Partners, ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

Bookrunners of European Leveraged Loans

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 BNP Paribas 5,388.55 35 7.45%
2 Credit Agricole CIB 5,167.13 26 7.14%
3 Deutsche Bank 5,163.07 27 7.14%
4 Goldman Sachs 4,132.89 22 5.71%
5 JPMorgan 4,083.96 19 5.65%

Bookrunners of European HY Bonds

Rank Lead Manager Amount €m No of issues Share %
  • Last updated
  • Today
1 Deutsche Bank 2,970.40 18 8.44%
2 Citi 2,605.77 18 7.40%
3 BNP Paribas 2,567.12 24 7.29%
4 JPMorgan 2,467.56 18 7.01%
5 Goldman Sachs 1,928.73 16 5.48%

Bookrunners of Dollar Denominated HY Bonds

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 JPMorgan 13,711.91 110 9.94%
2 Citi 12,738.91 102 9.24%
3 Goldman Sachs 9,904.15 73 7.18%
4 Bank of America Merrill Lynch 9,863.78 84 7.15%
5 Morgan Stanley 8,144.98 61 5.90%